Tilt Investment Management Holdings PBC Sells 56,080 Shares of Pfizer Inc. (NYSE:PFE)

Tilt Investment Management Holdings PBC cut its holdings in Pfizer Inc. (NYSE:PFE) by 71.8% in the fourth quarter, HoldingsChannel reports. The firm owned 21,983 shares of the biopharmaceutical company’s stock after selling 56,080 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Pfizer were worth $633,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. RB Capital Management LLC raised its holdings in Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its position in Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank lifted its holdings in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC boosted its stake in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp raised its position in Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.4 %

PFE stock traded down $0.09 during trading on Thursday, hitting $25.33. 25,646,090 shares of the company’s stock traded hands, compared to its average volume of 42,343,496. The firm has a market capitalization of $143.43 billion, a P/E ratio of 70.25, a PEG ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.56. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $27.19 and a two-hundred day simple moving average of $28.76.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue was down 41.3% compared to the same quarter last year. During the same period last year, the business posted $1.14 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.